2023
Nwikue, G., Olsson-Brown, A., Aboheimed, N., Yip, V., Jolly, C., Luchian, A., . . . Carr, D. F. (2023). TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis. JOURNAL OF DERMATOLOGY, 50(9), 1129-1139. doi:10.1111/1346-8138.16847DOI: 10.1111/1346-8138.16847
Ball, A. L., Jolly, C. E., Lennon, M. G., Lyon, J. J., Alfirevic, A., & Chadwick, A. E. (2023). The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury. ELIFE, 12. doi:10.7554/eLife.78187DOI: 10.7554/eLife.78187
Olsson-Brown, A., Yip, V., Ogiji, E. D., Jolly, C., Ressel, L., Sharma, A., . . . Carr, D. F. (2023). TNF-α-Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 143(6), 1023-+. doi:10.1016/j.jid.2022.11.024DOI: 10.1016/j.jid.2022.11.024
2022
Hammond, S., Olsson-Brown, A., Grice, S., Gibson, A., Gardner, J., Castrejon-Flores, J. L., . . . Naisbitt, D. J. (2022). Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. TOXICOLOGICAL SCIENCES, 186(1), 58-69. doi:10.1093/toxsci/kfab144DOI: 10.1093/toxsci/kfab144
2021
Sasson, S. C., Wilkins, L. E., Watson, R. A., Jolly, C., Brain, O., Klenerman, P., . . . Fairfax, B. P. (2021). Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.. Scientific reports, 11(1), 19253. doi:10.1038/s41598-021-98700-7DOI: 10.1038/s41598-021-98700-7
Hammond, S., Olsson-Brown, A., Gardner, J., Thomson, P., Ali, S. -E., Jolly, C., . . . Naisbitt, D. (2021). T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(5). doi:10.1136/jitc-2021-002521DOI: 10.1136/jitc-2021-002521
2020
Sasson, S. C., Zaunders, J. J., Nahar, K., Munier, C. M. L., Fairfax, B. P., Olsson-Brown, A., . . . Kelleher, A. D. (2020). Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.. Clinical and experimental immunology, 202(3), 335-352. doi:10.1111/cei.13502DOI: 10.1111/cei.13502
Jolly, C. E., Douglas, O., Kamalian, L., Jenkins, R. E., Beckett, A. J., Penman, S. L., . . . Chadwick, A. E. (2020). The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine.. Toxicology and applied pharmacology, 403, 115163. doi:10.1016/j.taap.2020.115163DOI: 10.1016/j.taap.2020.115163
2019
Kamalian, L., Douglas, O., Jolly, C. E., Snoeys, J., Simic, D., Monshouwer, M., . . . Chadwick, A. E. (2019). Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity.. Current protocols in toxicology, 80(01). doi:10.1002/cptx.76DOI: 10.1002/cptx.76
2018
Kamalian, L., Douglas, O., Jolly, C. E., Snoeys, J., Simic, D., Monshouwer, M., . . . Chadwick, A. E. (2018). The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity. TOXICOLOGY IN VITRO, 53, 136-147. doi:10.1016/j.tiv.2018.08.001DOI: 10.1016/j.tiv.2018.08.001
Evaluating Mitotoxicity as Either a Single or Multi‐Mechanistic Insult in the Context of Hepatotoxicity (Chapter)
Ball, A. L., Kamalian, L., Jolly, C. E., & Chadwick, A. E. (2018). Evaluating Mitotoxicity as Either a Single or Multi‐Mechanistic Insult in the Context of Hepatotoxicity. In Unknown Book (pp. 73-92). Wiley. doi:10.1002/9781119329725.ch6DOI: 10.1002/9781119329725.ch6
